Press Releases

Back

Julphar presents giant leap against Diabetes at UAE Innovation Week

2015-11-25
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa held a conference on Wednesday, 25th November to celebrate its success in Julphar Diabetes’ Human Insulin and Insulin Glargine.
 
The conference is part of the nationwide innovation week and was held at Julphar’s state-of-the-art recombinant Diabetes plant, a $150m manufacturing facility dedicated to producing raw material needed for Biosimilar products. 

The conference was attended by more than 70 health professionals from all over the Emirates, including medical institutions representatives, university students and professors, clinicians and media.

“It is an honour for us to take part in this nationwide event, and we are proud to support innovation in Ras Al Khaimah,” says His Highness Sheikh Faisal Bin Saqr Al Qassimi, Chairman of Julphar. “Diabetes is one of the key focus therapeutic areas for Julphar and we are committed to continue our investments in biotechnology and bio-similar insulins from raw materials to finished products.”

The data presented at the conference clearly demonstrated the excellent progress made by Julphar’s Insulin and Glargine in developing what is believed to become a new game-changing therapy for insulin-dependent diabetes. 

An informational session on the success behind Julphar Diabetes’ Human Insulin and Insulin Glargine was hosted by Senior Director Technical Operations Biotechnology, Eng. Essam Hammad and Chief Scientist Biotechnology, Dr. Talal Al Zaher. During the presentation, the hosts opened with the story of how Julphar Diabetes came to be. With the help and dedication of highly skilled scientists, engineers and chemists, a biotechnology platform was established. A 2 ton capacity facility, dedicated to the production of Human Insulin and Insulin analogues, was then set up, making Julphar the first producer of insulin in the region. 

The presentation was followed by an interactive tour of Julphar’s latest pharmaceutical biotechnology achievements around the facility.
 

Julphar presents giant leap against Diabetes at UAE Innovation Week
2015-11-25

 
 
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa held a conference on Wednesday, 25th November to celebrate its success in Julphar Diabetes’ Human Insulin and Insulin Glargine.
 
The conference is part of the nationwide innovation week and was held at Julphar’s state-of-the-art recombinant Diabetes plant, a $150m manufacturing facility dedicated to producing raw material needed for Biosimilar products. 

The conference was attended by more than 70 health professionals from all over the Emirates, including medical institutions representatives, university students and professors, clinicians and media.

“It is an honour for us to take part in this nationwide event, and we are proud to support innovation in Ras Al Khaimah,” says His Highness Sheikh Faisal Bin Saqr Al Qassimi, Chairman of Julphar. “Diabetes is one of the key focus therapeutic areas for Julphar and we are committed to continue our investments in biotechnology and bio-similar insulins from raw materials to finished products.”

The data presented at the conference clearly demonstrated the excellent progress made by Julphar’s Insulin and Glargine in developing what is believed to become a new game-changing therapy for insulin-dependent diabetes. 

An informational session on the success behind Julphar Diabetes’ Human Insulin and Insulin Glargine was hosted by Senior Director Technical Operations Biotechnology, Eng. Essam Hammad and Chief Scientist Biotechnology, Dr. Talal Al Zaher. During the presentation, the hosts opened with the story of how Julphar Diabetes came to be. With the help and dedication of highly skilled scientists, engineers and chemists, a biotechnology platform was established. A 2 ton capacity facility, dedicated to the production of Human Insulin and Insulin analogues, was then set up, making Julphar the first producer of insulin in the region. 

The presentation was followed by an interactive tour of Julphar’s latest pharmaceutical biotechnology achievements around the facility.